221 related articles for article (PubMed ID: 15117932)
1. Antibiotic treatment of gram-positive bone and joint infections.
Darley ES; MacGowan AP
J Antimicrob Chemother; 2004 Jun; 53(6):928-35. PubMed ID: 15117932
[TBL] [Abstract][Full Text] [Related]
2. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
[TBL] [Abstract][Full Text] [Related]
3. Role of linezolid in the treatment of orthopedic infections.
Bassetti M; Righi E; Di Biagio A; Rosso R; Beltrame A; Bassetti D
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):343-52. PubMed ID: 15954851
[TBL] [Abstract][Full Text] [Related]
4. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
Jankowski A; Stefanik W
Wiad Lek; 2006; 59(9-10):727-31. PubMed ID: 17338140
[TBL] [Abstract][Full Text] [Related]
5. Linezolid in the treatment of Gram-positive prosthetic joint infections.
Bassetti M; Vitale F; Melica G; Righi E; Di Biagio A; Molfetta L; Pipino F; Cruciani M; Bassetti D
J Antimicrob Chemother; 2005 Mar; 55(3):387-90. PubMed ID: 15705640
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
9. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
11. [Peptostreptococcus magnus osteoarticular infections after orthopedic surgery. 14 cases and pathogenicity factors].
Felten A; Desplaces N; Nizard R; Sedel L; Lagrange P
Pathol Biol (Paris); 1998 Jun; 46(6):442-8. PubMed ID: 9769879
[TBL] [Abstract][Full Text] [Related]
12. [Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)].
Grimprel E; Lorrot M; Haas H; Pinquier D; Parez N; Ferroni A; Cohen R;
Arch Pediatr; 2008 Oct; 15 Suppl 2():S74-80. PubMed ID: 19000859
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin in bone and joint infections: a review of the literature.
Rice DA; Mendez-Vigo L
Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
[TBL] [Abstract][Full Text] [Related]
14. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
[TBL] [Abstract][Full Text] [Related]
15. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
16. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
17. New antibiotic agents for bloodstream infections.
Vergidis PI; Falagas ME
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
19. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
20. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
